Mosaic ImmunoEngineering Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
CPMVStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(687,846) | $(921,983) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation | – | 4,867 |
| Non-cash interest on convertible notes | 73,332 | 73,533 |
| Accretion to redemption value on convertible notes | – | 1,446 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 10,332 | (3,237) |
| Accounts payable | (2,081) | (16,387) |
| Accrued compensation | 486,556 | 582,741 |
| Accrued expenses and other | 8,310 | 5,087 |
| Net cash used in operating activities | (111,397) | (241,159) |
| Financing activities: | ||
| Proceeds from the issuance of loans payable | – | 270,000 |
| Payments on loan payables | – | (70,000) |
| Net cash provided by financing activities | – | 200,000 |
| Net change in cash and cash equivalents | (111,397) | (41,159) |
| Cash and cash equivalents, beginning of period | 115,019 | 156,178 |
| Cash and cash equivalents, end of period | $3,622 | $115,019 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | $2,400 | $2,400 |
| Cash paid for interest on loan payable | $– | $6,214 |
Mosaic ImmunoEngineering, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.